Cargando…

Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients

Cystic fibrosis (CF) is a hereditary disease that is characterized by defective mucociliary clearance, airway obstruction, chronic infection, and persistent inflammation. Cystic fibrosis pulmonary exacerbation (CFPE) majorly causes the morbidity of CF patients. Although CF has been demonstrated to c...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qi, Wang, Yaqiang, Xia, Yao, Li, Lianwei, Luo, Juan, Xia, Shuxian, Sun, Yang, Miao, Yinglei, Wang, Kunhua, Chen, Ye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156045/
https://www.ncbi.nlm.nih.gov/pubmed/30212959
http://dx.doi.org/10.1097/MD.0000000000012248
_version_ 1783358020744380416
author Huang, Qi
Wang, Yaqiang
Xia, Yao
Li, Lianwei
Luo, Juan
Xia, Shuxian
Sun, Yang
Miao, Yinglei
Wang, Kunhua
Chen, Ye
author_facet Huang, Qi
Wang, Yaqiang
Xia, Yao
Li, Lianwei
Luo, Juan
Xia, Shuxian
Sun, Yang
Miao, Yinglei
Wang, Kunhua
Chen, Ye
author_sort Huang, Qi
collection PubMed
description Cystic fibrosis (CF) is a hereditary disease that is characterized by defective mucociliary clearance, airway obstruction, chronic infection, and persistent inflammation. Cystic fibrosis pulmonary exacerbation (CFPE) majorly causes the morbidity of CF patients. Although CF has been demonstrated to change the composition of lung microbial community, previous studies have not made efforts to study the differences in the mechanism of assembly and diversity maintenance of lung microbial community in CF patients. In this study, we applied the neutral theory of biodiversity to comparatively investigate the assembly and diversity maintenance of the lung microbial community before and after the antibiotic treatment by reanalyzing the dataset from Fodor et al's study. We found that no one sample in the lung microbial communities of the sputum samples of Exacerbation group, nor those of End-of-treatment group satisfied the predictions of neutral model, suggesting that the neutral-process does not dominate in CF patients before and after antibiotic treatments. By comparing the biodiversity parameter between Exacerbation and End-of-treatment group, we found that the former had the significantly higher biodiversity, but the change in diversity parameter is slight and the P value is close to.05 (P value = .41). Therefore, our second finding is that although CFPE may increase the biodiversity of lung microbial community, the change is not essential.
format Online
Article
Text
id pubmed-6156045
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-61560452018-11-08 Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients Huang, Qi Wang, Yaqiang Xia, Yao Li, Lianwei Luo, Juan Xia, Shuxian Sun, Yang Miao, Yinglei Wang, Kunhua Chen, Ye Medicine (Baltimore) Research Article Cystic fibrosis (CF) is a hereditary disease that is characterized by defective mucociliary clearance, airway obstruction, chronic infection, and persistent inflammation. Cystic fibrosis pulmonary exacerbation (CFPE) majorly causes the morbidity of CF patients. Although CF has been demonstrated to change the composition of lung microbial community, previous studies have not made efforts to study the differences in the mechanism of assembly and diversity maintenance of lung microbial community in CF patients. In this study, we applied the neutral theory of biodiversity to comparatively investigate the assembly and diversity maintenance of the lung microbial community before and after the antibiotic treatment by reanalyzing the dataset from Fodor et al's study. We found that no one sample in the lung microbial communities of the sputum samples of Exacerbation group, nor those of End-of-treatment group satisfied the predictions of neutral model, suggesting that the neutral-process does not dominate in CF patients before and after antibiotic treatments. By comparing the biodiversity parameter between Exacerbation and End-of-treatment group, we found that the former had the significantly higher biodiversity, but the change in diversity parameter is slight and the P value is close to.05 (P value = .41). Therefore, our second finding is that although CFPE may increase the biodiversity of lung microbial community, the change is not essential. Wolters Kluwer Health 2018-09-14 /pmc/articles/PMC6156045/ /pubmed/30212959 http://dx.doi.org/10.1097/MD.0000000000012248 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0
spellingShingle Research Article
Huang, Qi
Wang, Yaqiang
Xia, Yao
Li, Lianwei
Luo, Juan
Xia, Shuxian
Sun, Yang
Miao, Yinglei
Wang, Kunhua
Chen, Ye
Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients
title Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients
title_full Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients
title_fullStr Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients
title_full_unstemmed Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients
title_short Testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients
title_sort testing the neutral theory of biodiversity with the microbiome dataset from cystic fibrosis patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156045/
https://www.ncbi.nlm.nih.gov/pubmed/30212959
http://dx.doi.org/10.1097/MD.0000000000012248
work_keys_str_mv AT huangqi testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT wangyaqiang testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT xiayao testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT lilianwei testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT luojuan testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT xiashuxian testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT sunyang testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT miaoyinglei testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT wangkunhua testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients
AT chenye testingtheneutraltheoryofbiodiversitywiththemicrobiomedatasetfromcysticfibrosispatients